ArticleAMB Express2025
Perennial ryegrass improves bone quality in geese: insights from the gut-bone axis.
Article in AMB Express, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Bone disorders are marked by leg deformities, and disruption in the gut microbiota have been associated with degradation of bone structure, which increases the susceptibility of fractures. Perennial ryegrass has antimicrobial, antioxidant and anti-inflammatory properties to improve bone health by regulating the gut microbiota. In this study, we investigated the anti-inflammatory potential of perennial ryegrass to modulate the inflammatory bone loss in meat geese through regulating gut microbiota. Perennial ryegrass (GD) significantly reduced (p < 0.05) the inflammatory response (IL-1β and TNF-α) by improving the gut barrier function. Perennial ryegrass (GD) improved tibia bone mineral density (BMD), ash% and tibia bone mineral contents (p < 0.05). Results of gut microbiota and micro-computed tomography analysis showed that the beneficial effect of GD on bone mass might be associated with higher relative abundance of short-chain fatty acids (SCFAs) producing gut microbiota in the cecum by improving microbial diversity as compared to commercial feeding (CD). Regarding bone turnover, GD increased bone formation markers such alkaline phosphatase (ALP), runt-related transcription factor 2 (RUNX2), osteoprotegerin (OPG), osteocalcin (OCN), mothers against decapentaplegic homolog (SMAD) expression by reducing the nuclear factor-kappa B (NF-κB) expression and bone resorption markers i.e. nuclear factor of activated T-cells, cytoplasmic 1 (NFATC1) and tumor necrosis factor receptor associated factor 6 (TRAF-6). Perennial ryegrass exhibited an increase in antioxidant potential by reducing the malondialdehyde (MDA) and reactive oxygen species (ROS) production leading to increased catalase (CAT) and glutathione per oxidase (GSH-PX) levels (P < 0.05). Western blot and Immunofluorescence analysis of tibia showed reduced expression of NF-κB in GD group. These results indicate the importance of perennial ryegrass in alleviating bone loss through gut microbiota via NF-κB signaling mechanism. These findings emphasize the significance of the gut-bone axis and offer new insights into the role of perennial ryegrass in promoting bone health.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.